SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-058201
Filing Date
2024-05-13
Accepted
2024-05-13 07:30:45
Documents
84
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q qncx-20240331.htm   iXBRL 10-Q 2515714
2 EX-31.1 qncx-ex31_1.htm EX-31.1 13224
3 EX-31.2 qncx-ex31_2.htm EX-31.2 13282
4 EX-32.1 qncx-ex32_1.htm EX-32.1 10290
5 EX-32.2 qncx-ex32_2.htm EX-32.2 10348
6 GRAPHIC img175908028_0.jpg GRAPHIC 551208
7 GRAPHIC img175908028_1.jpg GRAPHIC 109661
8 GRAPHIC img175908028_2.jpg GRAPHIC 291440
9 GRAPHIC img175908028_3.jpg GRAPHIC 261137
10 GRAPHIC img175908028_4.jpg GRAPHIC 312188
  Complete submission text file 0000950170-24-058201.txt   14065531

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT qncx-20240331.xsd EX-101.SCH 1530293
87 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20240331_htm.xml XML 1998038
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38890 | Film No.: 24936880
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)